Short answer
Sana Biotechnology, Inc. (SANA) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Reg FD disclosure consists only of legal furnishing language; substantive information is in Exhibit 99.1.
Sana Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure consists only of legal furnishing language; substantive information is in Exhibit 99.1
- Information not deemed “filed” under Exchange Act Section 18, limiting associated liability exposure
Item EX-99.1 · Exhibit EX-99.1
- SC451 IND filing and Phase 1/2 initiation targeted for 2026, creating near-term clinical catalysts in type 1 diabetes
- UP421 demonstrated hypoimmune islet-cell survival and function through 14 months without immunosuppression
- UP421 met all primary and secondary endpoints with no therapy-related adverse events reported
- SG293 showed 15–20% circulating CD8+ T-cell transduction in NHPs, complete B-cell depletion, and potential NHL data in 1H 2027
- SG227 multiple-myeloma clinical study could begin as early as 2027, expanding Sana’s in-vivo CAR-T opportunity beyond diabetes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sana Biotechnology, Inc. 8-K filings
Get the next SANA 8-K as it lands
Follow SANA for push alerts, or ask the research agent what this filing means.